Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.
A prospective, single arm, continued access protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers having one or more of the following characteristics:
A maximum of 21 sites will enroll up to 184 transplanted liver recipients. The primary effectiveness endpoint will be the incidence of Early Allograft Dysfunction (EAD) or primary non-function.
All recipients will be followed for 24 months from the date of transplantation (some of which will be post-market).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OCS Liver System | Device | OCS Liver System for preserving and assessing donor livers for transplantation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants With Early Liver Allograft Dysfunction (EAD) | Participants with Early liver Allograft Dysfunction (EAD) or primary non-function, defined as presence of one or more of the following criteria: AST level > 2000 IU/ml within the first 7 postoperative days; Bilirubin ≥ 10 mg/dl on postoperative day 7; INR ≥ 1.6 on postoperative day 7; or Primary non-functioning graft within the first 7 days (defined as irreversible graft dysfunction requiring emergency liver re-transplantation or death, in the absence of immunologic or surgical causes) | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Survival at Day 30 After Transplant | Patient survival at day 30 post transplantation. | 30 days after transplant |
Not provided
Recipient Inclusion Criteria:
Exclusion Criteria:
Donor Inclusion Criteria
Donor Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ahmed Elbetanony, MD | TransMedics | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scripps | La Jolla | California | 92037 | United States | ||
| University of California San Diego |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33650998 | Derived | Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant. 2021 Apr 1;26(2):168-175. doi: 10.1097/MOT.0000000000000866. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment Arm | OCS Liver System: OCS Liver System for preserving and assessing donor livers for transplantation |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 9, 2019 |
Not provided
Not provided
Prospective, single-arm, continued access protocol
Not provided
Not provided
Not provided
Not provided
| La Jolla |
| California |
| 92037 |
| United States |
| UCSF | San Francisco | California | 94143 | United States |
| Tampa General | Tampa | Florida | 33606 | United States |
| Johns Hopkins | Baltimore | Maryland | 21205 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Henry Ford Hospital | Detroit | Michigan | 48202 | United States |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | United States |
| Mount Sinai Hospital | New York | New York | 10029 | United States |
| Montefiore Einstein Center for Transplantation | The Bronx | New York | 10467 | United States |
| Ohio State University | Columbus | Ohio | 43210 | United States |
| Methodist University Hospital | Memphis | Tennessee | 38104 | United States |
| University of Texas Southwest | Dallas | Texas | 75390 | United States |
| Houston Methodist Hospital | Houston | Texas | 77030 | United States |
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | United States |
| University of Virginia | Charlottesville | Virginia | 22903 | United States |
| Virginia Commonwealth University Health System | Richmond | Virginia | 23298 | United States |
| COMPLETED | Completing the 30 day visit. |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Treatment Arm | OCS Liver System: OCS Liver System for preserving and assessing donor livers for transplantation |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participants With Early Liver Allograft Dysfunction (EAD) | Participants with Early liver Allograft Dysfunction (EAD) or primary non-function, defined as presence of one or more of the following criteria: AST level > 2000 IU/ml within the first 7 postoperative days; Bilirubin ≥ 10 mg/dl on postoperative day 7; INR ≥ 1.6 on postoperative day 7; or Primary non-functioning graft within the first 7 days (defined as irreversible graft dysfunction requiring emergency liver re-transplantation or death, in the absence of immunologic or surgical causes) | Posted | Count of Participants | Participants | 7 days |
|
|
| |||||||||||||||||||||||||||
| Secondary | Patient Survival at Day 30 After Transplant | Patient survival at day 30 post transplantation. | Posted | Count of Participants | Participants | 30 days after transplant |
|
|
|
Liver graft-related serious adverse events (LGRSAEs) were collected up to the 30-day follow-up after transplantation for the safety endpoint. All-cause mortality is reported through 30-days post transplant.
Only death and serious adverse events were assessed.
Other (Not Including Serious) Adverse Events were not monitored/assessed, and therefore are not reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment Arm | OCS Liver System: OCS Liver System for preserving and assessing donor livers for transplantation | 1 | 74 | 4 | 74 | 0 | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hepatic artery thrombosis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Hepatic artery stenosis | Hepatobiliary disorders | Systematic Assessment |
|
Not provided
Sites shall have right to publish results. To balance this right with TransMedics' (TM) proprietary interests, site will submit manuscripts intended for publication for TM review at least 30 days prior to submission date. TM will complete its review within 30 days of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Laura Damme, VP Clinical Affairs | TransMedics, Inc. | 978-552-0900 | ldamme@transmedics.com |
| Apr 5, 2024 |
| Prot_SAP_000.pdf |
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|